A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

He Jiankui spent three years in prison after creating gene-edited babies. Now back at work, he sees a greater opening for ...

An international team including researchers from Nvidia and Microsoft has used AI on a biological trove of more than a ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Researchers have unveiled a way to flip genes back on without slicing into the genome, a shift that could make CRISPR far ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

This will be a conference call of the international commission developing a framework for considering technical, scientific, medical, regulatory, and ethical requirements for germline genome editing ( ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

A multidisciplinary committee of experts studied the scientific underpinnings of human gene-editing technologies, their potential use in biomedical research and medicine -- including human germline ...